TVRD Tvardi Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • New clinical trial data risk: Phase 2 trial of TTI-101 in IPF failed primary goals as of October 2025, triggering additional analyses and uncertain next steps
• • Most materially updated financial risk: Cash and equivalents $21.4M, short-term investments $15.0M as of Sept 30, 2025, significant doubt about going concern status

What are the latest TVRD SEC filings in 2026?

Tvardi Therapeutics, Inc. (TVRD) has filed a 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on March 31, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TVRD file its most recent 10-K annual report?

Tvardi Therapeutics, Inc. (TVRD) filed its most recent 10-K annual report on March 31, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TVRD 10-Q quarterly reports?

Tvardi Therapeutics, Inc. (TVRD)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every TVRD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TVRD filed recently?

Tvardi Therapeutics, Inc. (TVRD)'s most recent 8-K was filed on March 31, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TVRD insider trading activity (Form 4)?

SignalX aggregates every TVRD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TVRD file with the SEC?

Tvardi Therapeutics, Inc. (TVRD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TVRD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Tvardi Therapeutics, Inc. (TVRD).

What is TVRD's SEC CIK number?

Tvardi Therapeutics, Inc. (TVRD)'s SEC CIK (Central Index Key) number is 1346830. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1346830 to look up all TVRD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TVRD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Tvardi Therapeutics, Inc. (TVRD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.